Virtu Financial’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-1,038
Closed -$9K – 2054
2025
Q4
$9K Buy
+1,038
New +$18.3K ﹤0.01% 1520
2024
Q3
– Sell
-54
Closed -$6K – 1698
2024
Q2
$6K Buy
+54
New +$7.34K ﹤0.01% 1174
2024
Q1
– Sell
-217
Closed -$35K – 1838
2023
Q4
$35K Buy
+217
New +$36.7K ﹤0.01% 1230
2023
Q3
– Sell
-120
Closed -$33K – 1668
2023
Q2
$33K Buy
+120
New +$42K ﹤0.01% 1187
2023
Q1
– Sell
-192
Closed -$72K – 1869
2022
Q4
$72K Buy
192
+157
+449% +$78.3K 0.01% 1020
2022
Q3
$17K Sell
35
-88
-72% -$51.8K ﹤0.01% 1434
2022
Q2
$73K Buy
+123
New +$70.3K 0.01% 1011
2022
Q1
– Sell
-113
Closed -$86K – 1828
2021
Q4
$86K Sell
113
-195
-63% -$156K 0.01% 1187
2021
Q3
$300K Buy
+308
New +$199K 0.03% 714
2021
Q1
– Sell
-63
Closed -$64K – 1873
2020
Q4
$64K Buy
+63
New +$43.8K 0.01% 1181
2019
Q4
$333K Buy
+196
New +$170K 0.03% 620
2019
Q3
– Sell
-40
Closed -$25K – 1686
2019
Q2
$25K Sell
40
-116
-74% -$83.6K ﹤0.01% 1318
2019
Q1
$127K Buy
156
+70
+81% +$56.6K 0.01% 1093
2018
Q4
$39K Buy
+86
New +$50.6K ﹤0.01% 1303
2018
Q1
– Sell
-142
Closed -$123K – 2358
2017
Q4
$123K Buy
142
+79
+125% +$76.2K 0.01% 1851
2017
Q3
$62K Buy
+63
New +$63.1K ﹤0.01% 2193

Other funds holding MTNB

Virtu Financial's MTNB Position: Q1 2026 in Review

Virtu Financial sold out of Matinas BioPharma (MTNB) in Q1 2026, closing a stake of 1,038 shares — an estimated $9K sold.

Virtu Financial first reported a position in MTNB in Q3 2017 and held it in 16 quarters. The position peaked at $333K in Q4 2019. 24 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

  • Virtu Financial reported no remaining Matinas BioPharma position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 1,038 Matinas BioPharma shares in Q1 2026, an estimated $9K.
  • Virtu Financial first reported a position in Matinas BioPharma in Q3 2017 and held it in 16 quarters.
  • Virtu Financial's Matinas BioPharma position peaked at $333K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.